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Abstract
BACKGROUND & AIMS—In patients with hepatitis C virus (HCV) infection, interferon alfa
(IFN-α) alters expression of IFN-stimulated genes (ISGs), but little is understood about factors
that determine outcomes of therapy. We used a systems biology approach to evaluate the acute
response of patients with chronic hepatitis C to IFN-α therapy.
METHODS—We collected liver biopsy samples from 8 treatment-naïve patients with chronic
HCV genotype 1 infection at baseline and 24 hours after treatment with IFN-α-2a (10 MU
subcutaneously). Blood samples were collected before and up to 48 hours after administration of
IFN-α-2a to measure HCV RNA levels and for gene expression analysis. Patients then received
pegylated IFN-α-2a and ribavirin on day 5 of the study; therapy continued for up to 48 weeks.
RESULTS—Based on the kinetics of HCV RNA during the first 12 weeks of therapy, 2 patients
were rapid virologic responders, 4 were early virologic responders, and 2 did not respond to
therapy (nonresponders). Nonresponders had high pretreatment levels of ISG expression in the
liver but not in peripheral blood mononuclear cells. In responders, after administration of IFN-α,
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intrahepatic ISG expression increased significantly from baseline and was associated with a rapid
phase 1 decrease in HCV. We identified distinct hepatic expression and tissue distribution patterns
of ISGs that segregated with treatment outcome. Importantly, Kupffer cells were a local source of
IFN that promoted basal expression of ISG in hepatocytes of non-responders. This finding was
validated in cultured THP1 human macrophages that expressed IFN-β after exposure to viable
HCV 2a. When Huh7 K2040 and Huh7 L2198S hepatoma cells were incubated with IFN-α-2a,
expression of ISGs peaked by 4 hours and decreased by 72 hours, associated with an increase in
level of HCV RNA. This indicates that constitutive exposure to IFN causes hepatoma cells to
become tolerant of ISG function.
CONCLUSIONS—In patients with chronic HCV infection, IFN production by Kupffer cells
might promote innate immune tolerance, characterized by a lack of response to IFN therapy.
Strategies to disrupt the virus-host interactions that induce innate immune tolerance should
improve therapy.
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Patients with hepatitis C virus (HCV) infection are treated with interferon (IFN)-α–based
therapy.1 Although the recent approval of the HCV-specific protease inhibitors marks a
significant advance in the treatment of patients with chronic hepatitis C, the combination of
IFN-α and ribivirin remains the platform with which such direct-acting antivirals are used in
HCV treatment.1 This underscores the need to understand the actions of IFN-α in vivo to
design the most effective antiviral regimen for the treatment of patients with HCV.
Treatment with IFN induces the expression of hundreds of interferon-stimulated genes
(ISGs) in responding cells.2,3 ISG products serve as immune effectors to impart cellular
response pathways of innate immunity and others to drive the global antiviral actions that
suppress HCV infection.3 Moreover, IFN serves to support and modulate the adaptive
immune response through specific ISGs expressed in immune cells.4,5 However, the system-
wide and hepatic responses to IFN among patients with HCV and how these responses
contribute to differential therapeutic outcomes are still not well understood.2
We specifically evaluated the acute response to IFN-α in vivo after the first 24 hours of
treatment in patients with HCV genotype 1 infection and modeled this response in vitro. Our
results show tissue- and cell-specific response compartmentalization that links local IFN-β
production by Kupffer cells to a hepatic ISG expression set point as a central feature of
“innate immune tolerance” that mitigates the response to IFN therapy.
Patients and Methods
Detailed information on methods is available in Supplementary Patients and Methods.
Treatment-naïve white and black patients with HCV genotype 1 who were 18 years of age or
older were enrolled in the study. Subjects underwent a baseline percutaneous liver biopsy on
day 1 of the study. A single dose of IFN-α (10 MU subcutaneously) was administered on
day 3, and a repeat liver biopsy for research purposes was performed 24 hours after
treatment. A total of 1 to 3 cm of the excess tissue was immediately preserved in a
commercial solution (RNAlater; Ambion, Austin, TX) for Affymetrix analysis (Affymetrix,
Inc, Santa Clara, CA). Fifteen-milliliter blood samples were drawn immediately before and
1, 3, 6, 12, 18, 24, 36, and 48 hours after treatment with IFN for quantitation of HCV RNA
and Affymetrix analysis. The first dose of pegylated IFN-α-2a and weight-based ribavirin
was administered on day 5, and therapy continued for up to 48 weeks as per the standard of
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care recommendation. The clinical study was approved by the institutional review board at
the University of Texas Medical Branch and Beth Israel Deaconess Medical Center. The
first 2 subjects were enrolled at the University of Texas Medical Branch at Galveston, and
all subsequent subjects were enrolled at Beth Israel Deaconess Medical Center. Study
procedures were identical.
HCV Kinetic Mathematical Modeling
To analyze the early HCV RNA kinetics in patients, we fit via nonlinear least squares
regression the natural logarithm of V(t) predicted by the equation V(t)= V0(1 − ε + ε
exp(−c(t − t0))), derived by Neumann et al to the natural logarithm of the serum viral load
data.6 When the drug effectiveness (ε) = 1, the virion production is fully suppressed; if ε = 0,
the production is unchanged. This equation is based on the assumption that the HCV RNA
level was in steady state before the initiation therapy and that the infected cell number
remained constant during the first 1 to 2 days of therapy.6,7
Liver and Peripheral Blood Mononuclear Cell Sample Preparation and Microarray Analysis
Immediately after liver biopsy, a portion of the tissue was placed into RNAlater (Ambion)
for storage at −70°C. Total RNA was extracted using the ToTALLY RNA Kit (Ambion).
Affymetrix HG-U133 2.0 Human GeneChips were used for all microarray experiments.
Microarray analyses were conducted exactly as described previously.8 The Affymetrix
methods used for the peripheral blood lymphocyte samples are similar.
Computational Analysis of Gene Expression Data Sets
Pre–IFN-treated liver samples were analyzed using one-way analysis of variance and
hierarchical clustering methods. The resulting genes that significantly differentiated the 3
patient groups at a P value of ≤.05 were expressed in a heat map using Spotfire Decision
Site software (TIBCO Spotfire, Somerville, MA). Functional and canonical pathways
analysis was performed using Ingenuity Pathways Analysis (Ingenuity Systems, Redwood
City, CA) on those significant genes with an absolute fold change of ≥1.4. Paired t test was
performed on pre-IFN and post-IFN gene expression levels using the robust
MultiExperiment Viewer (MeV 4.0; Dana Farber Cancer Institute, Boston, MA). After
hierarchical clustering, differentially expressed genes at a P value of ≤.001 were expressed
in a heat map using Spotfire Decision Site software. Genes with absolute fold change of ≥2
were further analyzed by Venn analysis of the 3 groups. Detailed analysis of the peripheral
blood mononuclear cell (PBMC) data set appears in Supplementary Patients and Methods.
Cell Culture
Huh7 and Huh7-K2040 are parental human hepatoma cells and a matching clonal cell line
harboring the HCV 1b K2040 or L2198S subgenomic replicon, respectively, and were
cultured as described.5 THP1 cells were maintained in culture medium supplemented with
10% fetal bovine serum, L-glutamine, and standard antibiotics and were differentiated into
adherent macrophage-like cells by treatment with phorbol myristate acetate. Cells were
treated, harvested, and analyzed as described in Supplementary Patients and Methods.
HCV preparation—HCV (strain JFH1) was produced in Huh7.5 cells exactly as
described.9 HCV was purified from cell culture supernatants through centrifugation over
sucrose gradients. Control virus-free Huh7 cell culture medium was centrifuged through
sucrose gradients for collection as a treatment-negative control. HCV infectivity was
measured as described.9 Virion and media control tested negative for endotoxin as assayed
using the limulus amebocyte lysate endotoxin assay (Cape Cod, Inc, Falmouth, MA).
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Immunohistochemical Staining and Confocal Microscopy
For analysis of sections of paraffin-embedded liver biopsies, we used a previously reported
procedure that involved 4 major steps, including deparaffinization of tissue, antigen
retrieval, tissue permeabilization, and immunostaining.8 Detailed procedures are described
in Supplementary Patients and Methods.
Results
Phase 1 Viral Kinetics Reveals Distinct Clinical Response Profiles to IFN Therapy
Acute IFN-α response profiling included 8 subjects (6 men and 2 women) chronically
infected with HCV genotype 1. Pretreatment HCV RNA titers ranged from 1.5 to 13.6 MIU/
mL (Supplementary Table 1). Based on their HCV RNA kinetics during the first 12 weeks
on therapy, 2 patients were classified as rapid virologic responders (RVRs), 4 were early
virologic responders (EVRs), and 2 were nonresponders (NRs) (Supplementary Table 1).
The mathematical model of Neumann et al6 was fit to the serial HCV RNA loads from each
individual patient obtained during the first 24 hours (phase 1 kinetic) after a single 10
million unit dose of standard IFN-α-2a. The 2 RVRs had a reduction in HCV RNA levels ≥2
log10 IU/mL within 24 hours, and their drug effectiveness (ε) in suppressing virus
production was >0.995 (Figure 1). In contrast, the 2 NRs had a decline in HCV RNA levels
≤1 log10 IU/mL within the same time interval and the ε was low (0.464 and 0.852,
respectively). The 4 EVRs had intermediate declines in HCV RNA levels, falling between
the RVRs and NRs, and had a mean ε of 0.932 (Figure 1A).
Hepatic Gene Expression Before Treatment and During the Phase 1 Response to IFN
Differentiates Response Groups
We analyzed global gene expression in pretreatment tissues from our cohort. Direct
comparison of gene expression profiles among patients revealed 930 genes that significantly
differentiate the 3 treatment responder groups at a P value of ≤.05. As shown in Figure 1B,
we observed a clear demarcation of the RVRs, EVRs, and NRs in 3 distinct gene clusters. Of
these 930 genes, 635 (68%) were increased in expression (up-regulated) in NRs compared
with RVRs and EVRs. In contrast, there were only 143 and 123 genes (15% and 13%),
respectively, that were up-regulated in RVRs and EVRs compared with NRs.
Computational analysis to assign response pathways to the 635 genes that were up-regulated
among NRs compared with RVRs and EVRs was subsequently performed. A total of 265 of
these genes belong to the categories of apoptosis (36%), cell cycle (18%), cell signaling
(15%), cellular development (14%), lipid metabolism (9%), and immune response (6%). In
total, these response pathways are indicative of the inflammatory and innate immune
response to HCV infection. Among these genes, 41 were known ISGs and pathway
modeling analysis identified STAT1, the major component of the IFN-induced transcription
factor ISFG3,10 as a central regulatory node of gene expression linked to a variety of ISGs
(Figure 1C and D). These results are consistent with IFN-α/β receptor signaling as the
intracellular effector pathway driving the high basal ISG expression in pretreatment NRs
compared with RVRs and EVRs (Figure 1C and D). However, the activation of the IFN-λ
signaling pathway could be an alternative explanation based on the bioinformatics
analysis.11
To assess the acute hepatic transcriptional response to treatment with IFN-α, we examined
gene expression in liver tissue recovered 24 hours after administration of IFN-α-2a. Figure
2A shows a hierarchical clustering of the 86 differentially expressed genes (P ≤ .001). These
data show that the EVRs and RVRs together formed distinct gene clusters from NRs and
feature a significant number of up-regulated genes 24 hours after administration of IFN-α.
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For the NRs, their pre-IFN and 24-hour post-IFN samples formed the same gene clusters,
revealing an overall lack of further increase in gene expression during the acute response to
IFN. Although the EVRs and RVRs had a higher number of genes expressed in response to
IFN treatment, there was a conserved set of 28 genes that were reduced in expression or
“down-regulated” in response to IFN (Supplementary Table 2).
Among the ISGs induced by treatment with IFN-α, there were members of the IFIT gene
family. ISG56, the product of IFIT1, is a potent antiviral protein that restricts HCV RNA
translation.12 Although expression of the IFIT1 genes can be induced through the HCV-
responsive RIG-I pathway to activate IRF-3, IFIT1 expression is also highly induced by
IFN.12 Because HCV can block the RIG-I pathway in infected cells,3,9 accordingly the basal
ISG expression was low or not present in these patients (Figure 2B). Thus, the induction of
ISGs is largely attributed to IFN signaling (Figure 2C). Additionally, a subset of ISGs with
known antiviral potency, including oligoadenylate synthetase (OAS), interferon-induced
transmembrane 1 (IFITM1), and the guanosine triphosphatase MX1, with expression
induced through IFN-α/β receptor signaling, were identified.10 These ISGs were induced
from a low or nonexpressed pretreatment level to a multiple-fold increase in RVRs and
EVRs (Figure 2B and C). By comparison, NRs exhibited a high pretreatment “set point”
expression level of ISGs without further induction on treatment with IFN (Figure 2C). Venn
analysis was performed to examine the induced genes and response pathways in RVRs and
EVRs. Using criteria with a P value of ≤.05 and fold changes ≥1.5, 16 unique ISGs common
to RVRs and EVRs were identified in the Ingenuity Pathways Analysis (Supplementary
Table 3). Pathway modeling assigned IRF-7, a STAT1-responsive gene and IFN-induced
transcription factor that serves to amplify the IFN response,3,10 as a major node linking the
expression of ISGs after IFN-α among responders, suggesting that the rapid response of
EVRs and RVRs to IFN involved response amplification through IRF-7 signaling (Figure
2D and E).
ISG Expression Patterns of the Acute Response to IFN Therapy
To define the acute systemic response to IFN-α, we conducted parallel comparison of the
IFN-induced gene profiles between PBMCs and liver samples from the patient cohorts
before and after treatment with IFN-α. Unlike the pretreatment hepatic gene profiles, the
baseline ISG expression in PBMCs was generally silent and similar among RVRs, EVRs,
and NRs (Supplementary Figure 1A). In all patients, induction of ISG was maximal in
PBMCs within the first 3 to 12 hours but was overall lowest in the NRs (Supplementary
Figure 1B). Thus, the pretreatment ISG expression set point and acute phase 1 response to
IFN are distinct between liver and systemic peripheral blood compartments, as previously
noted.13
We assessed both the tissue distribution and the cell type response to treatment with IFN.
Biopsy tissue sections were immunostained with antibodies against specific ISG-encoded
proteins and were analyzed by high-resolution laser scanning confocal microscopy.8 Tissues
were costained in sets to detect nucleus and IFIT1/OAS1, IFITM1/MX1, and MX1 with
CD68, a marker of Kupffer cells.14 In general, ISG expression was low or silent in
pretreatment tissue from RVRs and EVRs but was induced to a highly abundant state 24
hours after treatment with IFN (Figure 3A and B, upper and middle panels). Notably, OAS1
was expressed at a low basal level in all specimens examined, regardless of response
outcome. In general, the hepatic ISGs were expressed to already high levels within
pretreatment specimens from NRs (Figure 3A–D).
We further assessed IFN response patterns of ISG expression within the liver of treated
patients and observed 3 distinct patterns of acute response to IFN. The first was observed
only in tissue from EVRs and RVRs and was termed “confluent and overlapping” in that this
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response pattern occurred throughout the majority of the tissue section in which both ISG
products of each staining set were induced and abundant across hepatocytes (Figure 3E, top
panels). The second pattern was a “cell specific” response and occurred only within NRs
wherein side-by-side cells expressed distinct levels of ISG product indicative of different
IFN response potentials among each (Figure 3F, middle panels). The third response pattern
was also observed in NR patient tissue as a “focal response” wherein IFN-induced protein
expression was found only in focal regions of the tissue (Figure 3G, bottom panels). These
latter response patterns were present in both pre-treatment and treatment NR tissue. Thus,
the hepatic response to IFN exhibits distinctions in ISG expression pretreatment set point,
uniformity, and cell type specificity that may impart a differential outcome to therapy for
HCV infection. We found that in some cases the ISG expression pattern included specific
differences in IFN-induced protein levels between hepatocytes and Kupffer cells, resident
hepatic macrophages. In particular, we found that NR patient tissue often exhibited
pretreatment Kupffer cell expression of MX1 surrounded by a halo of MX1-expressing
hepatocytes (Figure 3F).
The basal ISG expression within hepatocytes and Kupffer cells observed within NRs
suggests that IFN was being produced and secreted by Kupffer cells to drive a paracrine
pretreatment IFN response. To assess whether Kupffer cells within the liver were producing
IFN endogenously, we stained liver tissue with antibody specific for IFN-β in combination
with anti-CD68. As shown in Figure 4A, these analyses identified CD68+ Kupffer cells
harboring low but detectable levels of IFN-β specifically within NRs and showing a
peripheral staining pattern indicative of ongoing IFN-β secretion.
To determine if HCV exposure and/or uptake by Kupffer cells might induce their production
of IFN, we modeled HCV exposure in vitro at a multiplicity of infection corresponding to
0.1 focus-forming units based on Huh7 cells per milliliter using differentiated THP1 human
macrophage cells. Exposure of THP1 cells to viable HCV 2a but not control Huh7 culture
media resulted in IFN-β protein expression (Figure 4B). Moreover, exposure of THP1 to
HCV 2a also induced low-level expression of IFN-β messenger RNA (mRNA) (Figure 4C)
in which IFN-β was secreted into the culture supernatant of the former at 10 pg/mL as
determined by specific enzyme-linked immunosorbent assay. By comparison, 24 hours of
productive Sendai virus infection of THP1 cells induced a high level of IFN-β mRNA
(Figure 4C, far right bar). We found that HCV could actually enter THP1 cells and
transiently produce viral proteins through a process that was insensitive to anti-CD81
blocking antibodies (Figure 4D, left panel). Viral proteins, including the HCV NS3 protease,
were routinely detected in THP1 cells within 1 hour of HCV exposure, but their production
was only transient such that they became undetectable at time points beyond 6 hours after
virus exposure of cells (Figure 4D, right panel). Moreover, we observed MAVS expression
in HCV-treated THP1 cells with no indication of MAVS cleavage by the viral NS3 protease,
which targets and cleaves MAVS in infected hepatocytes as an immune evasion strategy.9
Lack of MAVS cleavage could be attributed to only low, transient levels of NS3 present in
THP1 cells. We also observed increased RIG-I levels beginning 6 hours after HCV exposure
of cells, consistent with the response to IFN-β. HCV RNA was present within THP1 cells
after HCV exposure but decayed over 72 hours (Figure 4E, left panel), whereas viral RNA
was amplified in Huh7 cells similarly exposed to HCV over this time course (Figure 4E,
right panel). When introduced in THP1 cells via lipophilic transfection, HCV RNA itself
was sufficient to trigger IFN-β expression (data not shown). We therefore assessed IFN-β
mRNA expression in THP1 cells deficient in RLR or specific TLR signaling function
through short hairpin RNA (shRNA) knockdown of MAVS or MyD88, respectively. THP1
cells harboring control nontargeting shRNA lentivirus or lentivirus-expressing shRNA
against MAVS or MyD88 were transfected with the HCV poly-U/UC motif RNA, a potent
pathogen-associated molecular pattern (PAMP) that stimulates IFN production (reviewed in
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Gale and Foy3). PAMP RNA was sufficient to trigger IFN-β expression in THP1 cells
expressing nontargeting control shRNA or MyD88 shRNA, but IFN-β expression was
blocked in cells expressing MAVS shRNA (Figure 4F, left panel). Treatment of cells with
cytochalasin D, which prevents phagocytosis, significantly reduced the uptake of HCV in
THP1 cells (Figure 4F, right panel). Treatment of cells with bafilomycin to disrupt
endosome acidification and receptor-mediated endocytosis had no effect on HCV uptake
(data not shown). These observations reveal phagocytosis as a critical cellular process in
mediating HCV uptake by macrophages. Our results show that while HCV fails to replicate
after macrophage uptake, the residual viral RNA can trigger intracellular MAVS-dependent
signaling of IFN-β expression. Thus, liver-resident myeloid lineage cells such as Kupffer
cells may take up HCV through phagocytic actions to trigger IFN-β production through
endogenous RLR signaling processes of IFN expression.
To determine how constitutive ISG expression could affect the cellular response of IFN, we
modeled the acute response to IFN therapy during chronic HCV RNA replication. Parallel
cultures of Huh7 K2040 and Huh7 L2198S cells15,16 were treated with IFN. ISG and HCV
RNA levels were evaluated over a time course. Cultures were then repeatedly treated 3 times
with IFN for 4 hours, and ISG expression and HCV RNA levels were measured after each
treatment. At baseline before administration of IFN-α-2a, ISG expression was minimal
(Figure 5A and B). The expression of the ISGs in Huh7 K2040 and Huh7 L2198S cells
peaked at 4 hours after treatment. By 72 hours, the levels of all ISGs were reduced. With
repeated IFN-α-2a treatments, there were progressively blunted responses of all ISGs
examined. Importantly, after the final round of sustained IFN-α2a treatment, ISG levels
exhibited a constitutively higher set point than their starting baseline values (see Figure 5A).
However, by 72 hours, the HCV RNA level began to increase. IFN-α-2a treatment of cells
beyond the first 72-hour period failed to suppress HCV RNA levels and overall mimicked
the NR patient phenotype of maintained viral load with an induced ISG set point. Because
the decay in HCV RNA within Huh K2040 cells showed faster than expected kinetics, we
also evaluated HCV RNA levels in IFN-treated Huh7 L2198S cells (Figure 5B). In this case,
the HCV RNA exhibited relatively lower levels and slower decay of viral RNA but showed
recovery similar to that of Huh7 K2040 cells to near-pretreatment levels after 72 hours of
treatment with IFN. In control experiments, we replaced the culture media of the replicon
cell lines with fresh media lacking IFN, and cultures were similarly assessed for HCV and
ISG RNA expression. In the absence of further treatment with IFN, the ISG set point and
HCV RNA levels returned to near baseline, implying that treatment with IFN imparts
control of ISG and HCV RNA levels in this culture model (Supplementary Figure 3). The
observed differences in HCV RNA decay rates between replicons reflect distinctions in
adaptive mutations of each HCV RNA15 and may also reflect clonal variation in RNA
metabolism processes among cell lines. Flow cytometric analysis revealed that IFN-α/β
receptor levels were increased on treatment with IFN-α-2a and maintained at a high level
throughout the duration of the experiment (Supplementary Figure 4). Thus, constitutive IFN
exposure and high ISG set are linked with the NR phenotype in vitro. These results imply
that constitutive exposure to IFN and actions of ISGs may drive a state of tolerance against
the therapeutic actions of IFN-α in which the hepatocyte is unable to fully respond and
suppress HCV.
Discussion
HCV can induce producton of IFN during de novo infection of hepatocytes as the virus
spreads from cell to cell within cell culture models and in the liver in chronic HCV.8,9
Secreted IFN-β induces a tissue-wide antiviral state via paracrine signaling to induce ISG
expression.3 However, within infected hepatocytes, the viral NS3/4A protein targets and
cleaves MAVS to suppress RIG-I signaling and ablate IFN production by hepatocytes.9,17
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Our results now define Kupffer cells as a possible source of hepatic IFN and suggest that
local IFN-β production by Kuppfer cells may drive ISG set point levels in surrounding
hepatocytes. Similarly, plasmacytoid dendritic cells can produce IFN when exposed to
HCV,18 and we have shown that plasmacytoid dendritic cells are abundantly present in the
liver in chronic HCV8 to possibly contribute a source of IFN.18 Although our study has a
limited sample size, the observations that hepatic ISG set point levels were inversely
associated with the outcome of IFN therapy are consistent with other studies.13,19–21 Thus,
hepatic IFN production from myeloid cell sources may underlie the poor outcome to IFN
therapy in these patients. Chen et al observed higher ISG15 levels within Kupffer cells of
responders. However, ISG15 expression was higher within hepatocytes of NRs.22
Expression and function of various, specific ISGs may thereby impart a differential therapy
outcome through cell-specific antiviral actions.
We show that Kupffer cells express IFN-β protein in vivo and that HCV can simulate
macrophage cell model induction of IFN on cell exposure in vitro. Our results reveal that
HCV can enter THP1 cells through phagocytic uptake, showing that HCV does not replicate
but instead decays after cell uptake. Because HCV RNA alone was sufficient to stimulate
THP1 cell IFN production, and IFN induction was blocked by knockdown of MAVS but not
MyD88 expression, we conclude that cell uptake of HCV leads to viral RNA interaction
with MAVS-dependent signaling actions of RIG-I. Thus, IFN induction in Kupffer cells
could be different from its induction in plasmacytoid dendritic cells, of which signaling
through TLR7/MyD88-dependent mechanisms serves to drive IFN expression by HCV.18
As a result of Kupffer cell IFN production, a high pretreatment ISG set point within
hepatocytes likely mitigates the cellular response to IFN by driving a state of tolerance to
ISG function, thus attentuating IFN actions and reducing the efficacy of therapy. We
observed that the phase 1 HCV RNA decline within the first 24 hours after treatment with
IFN-α correlated with the treatment response at 12 weeks. Among patients with differential
therapy responses, hepatic ISGs were expressed in specific patterns of uniform coexpression
within responding cells, cell type or cell-specific expression, or focal/localized expression.
Although the former pattern characterized our RVRs and EVRs, the other patterns were
prevalent within the liver of the NRs and associated with a high hepatic ISG set point.
Sarasin-Filipowicz et al noted that pretreatment ISG expression was not evident in PBMCs
of NRs,13 and we show here the same pattern of response in PBMCs. Our results link the
distinct patterns of hepatic ISG expression with therapy response outcome and suggest that
an effective therapeutic response to IFN is facilitated by tissue-wide ISG induction whereas
cell-specific and focal responses are limited in antiviral action. Thus, our results imply that
ISG protein distribution patterns serve to direct the outcome of the phase 1 virologic
response to IFN therapy. We examined the influences of the role of IL28B genotypes and
treatment response in a separate study (data not shown) and found similar results to those
first observed by Dill et al21 that high baseline ISG expression predicts the outcome of
therapy more strongly than IL28B genotype for nonresponse. These results, together with
the evidence of IFN-β secretion by Kupffer cells, support the role of type 1 IFN in inducing
the high basal ISG levels among nonresponders. However, it is important to evaluate the
potential influences of type III IFN in these ISG activation pathways.
Bioinformatic analyses revealed that in the liver, the responding ISGs were linked through a
central IRF-7 control node in RVRs and EVRs but not NRs, the latter of which exhibited
ISG expression primarily through the STAT1/ISGF3 signaling network. This difference of
ISG expression linked from an IRF-7 central node in responders but not NRs is an important
distinction that may affect the outcome of IFN therapy. IRF-7 plays a major role in
amplifying the IFN response through induction of IFN-α genes and by driving target ISG
expression.3 This lack of IRF-7 signaling among NRs could be expected to attenuate the
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expression of specific ISGs that otherwise respond to IRF-7, thus rendering the cells
“tolerant” to IFN therapy (see the following text). Unlike the hepatic response, ISG
induction in PBMCs occurred simultaneously among RVRs, EVRs, and NRs. The
separation of pretreatment ISG expression in the liver from PBMCs likely reflects the
production of IFN by Kupffer cells and other endogenous myeloid cells of the liver induced
through local exposure to HCV. This notion is supported by the assignment of STAT1 as the
central node of ISG expression in pretreatment NR liver, indicating that initial IFN signaling
but not amplification signaling was ongoing wherein the resulting cellular response imparts
hepatic tolerance to therapeutic IFN-α application.
We modeled chronic HCV replication in the presence of constitutive low levels of IFN to
validate the clinical observation of ISG tolerance in hepatocytes. Constitutive IFN-α
exposure in vitro generated a modest ISG set point level without an acute increase of ISG
expression on re-treatment with IFN-α. Furthermore, HCV RNA replication remained
relatively constant with repeated IFN-α treatment, indicating that the cells became tolerant
of IFN actions and/or that the HCV RNA replication process became tolerant to IFN. We
show that IFN causes a reduction in HCV RNA levels that then stabilize during prolonged
IFN exposure, likely reflecting tolerance to ISG expression and function. We propose a
model of “innate immune tolerance” in NRs in which endogenous IFN drives basal ISG
expression among hepatocytes. ISGs impart antiviral actions that when prolonged are
cytotoxic3,23 and, in the case of constitutive IFN exposure, ISG function must be tolerated
for the cell to survive, thus forcing a state of tolerance to IFN (Figure 6). We do not
precisely know why local IFN-β production by Kupffer cells is more readily observed in
NRs, but this could be due to an overall IFN amplification loop that enhances signaling
through IFN priming.23
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) Phase 1 HCV RNA kinetic after a single dose of IFN-α-2a (10 MU subcutaneously).
(B–D) Induction of differential hepatic genes and ISGs before administration of IFN-α. (B)
A heat map of RVRs, EVRs, and NRs shows distinct gene clusters. A total of 68% of the
significant genes were up-regulated in NRs. Ingenuity Pathways Analysis of ISG response
comparing (C) RVRs with NRs and (D) EVRs with NRs.
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Differential hepatic ISG induction after administration of IFN-α. (A) Heat map. (B)
Selective ISG signal intensity before administration of IFN-α (mean ± SD). *P < .05 (RVR
vs NR, or RVR vs EVR); +P < .05 (EVR vs NR). (C) Fold changes (mean ± SD) in hepatic
ISG after administration of IFN-α. *P < .05 (RVR vs NR, or RVR vs EVR); +P < .05 (EVR
vs NR). Ingenuity Pathways Analysis of up-regulated genes after administration of IFN-α in
(D) RVRs compared with NRs and (E) EVRs compared with NRs.
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Hepatic ISG expression distribution patterns in pretreatment and IFN-treated patients with
HCV (bar = 10 μmol/L). (A) Merged color confocal images of 0.2-μm liver sections
showing IFIT1 (red), OAS1 (green), and nuclei (blue). (B and C) Percent responding cells
expressing (B) OAS or (C) IFIT1 in liver sections from each patient group (mean ± SD).
Numbers were determined by counting stained cells within 10 different 40× magnification
fields from the patients in each group. (D) ISG protein distribution in 0.2-μm liver sections
showing merged confocal color images of immunostained tissue: MX1 (red), IFITM1
(green), and nuclei (blue). (E and F) Merged color confocal images showing different
patterns of IFIT1 (red) and OAS1 (green) distribution with nuclei (blue) in IFN-treated liver.
(E) Fluorescence signal intensity within the tissue distance denoted by vector (arrow) or
focal region (circle) in the far left panels is shown in histogram form in the accompanying
right panels. The top panels show confluent and overlapping distribution from an RVR, and
the middle panels show cell-specific distribution in an NR featuring differential ISG
expression in hepatocytes and neighboring Kupffer cells (upper middle panel) or among
adjacent hepatocytes (lower middle panel). The bottom panels show focal distribution of
ISG expression within responding hepatocyte clusters among background of nonresponding
cells in an NR. Histograms correspond to the signal intensity from specific costaining of
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nuclei (blue), IFIT1 (red), and OAS1 (green). (F) Merged micrograph of a pretreatment NR
patient liver showing nuclei (blue), MX1 (red), and CD68 (identifying Kupffer cells; green).
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IFN-β and CD68 expression. (A) Protein distribution in pretreatment HCV patient liver.
Liver sections were stained with anti–IFN-β (green), anti-CD68 (red), and nuclei (blue).
Panels show 0.3-μm optical sections of 40× merged confocal color images from an RVR
(upper panel) and 2 different NRs (lower panels). The far right panel shows a 60× close-up
of the area bounded by the yellow box in the NR panel. (B) Distribution of IFN-β and CD68
in immunostained THP1 cells. Cells were either mock treated or cultured with HCV (JFH1)
for 6 or 24 hours as indicated. HCV exposure of cells was based on a theoretical multiplicity
of infection (MOI) of 0.1 as determined by virus titration in Huh7 cells. Similar results were
obtained from THP1 cells exposed to HCV at an MOI of 0.3 (data not shown). (C) Fold
change (mean+/− SD) of IFN-β mRNA expression in mocked or HCV-exposed THP1 cells.
(D) HCV protein expression in cultured cells. (Left panel) HCV protein expression in THP1
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or Huh7.5 cells (lane 5) 36 hours after purified culture media mock or HCV (MOI of 0.1)
exposure. mIg and anti-CD81 denote cells pretreated with control immunoglobulin or anti-
CD81 blocking antibody before exposure to virus. (Right panel) THP1 cells were exposed to
media alone or HCV (MOI of 0.1) for the time indicated in hours. Panels show HCV NS3,
RIG-I, MAVS, and tubulin expression. The far right lane shows protein expression in HCV-
infected Huh7 cells. (E) (Left panel) HCV RNA levels in THP1 cells after mock or HCV
exposure shown in hours. No viral RNA was detectable by 96 hours after HCV exposure
(data not shown). HCV copy number (mean ± SD). (Right panel) HCV RNA levels in Huh7
cells shown in hours after HCV exposure. HCV copy number (mean ± SD). (F) (Left panel)
IFN-β mRNA levels in THP1 cells harboring nontargeting shRNA (control) or shRNA to
knock down (kd) the expression of MAVS or MyD88. Cells were treated with transfection
reagent alone (left panel) or transfected with the 100-nucleotide poly-U/UC PAMP RNA
motif encoded within the HCV genome RNA (PAMP RNA; right panel). Fold change (mean
± SD). Level of mRNA expression knockdown was compared with nontargeting shRNA
control and was >99% for MAVS shRNA and 90% for MyD88 shRNA as determined by
reverse-transcription quantitative polymerase chain reaction analysis of specific mRNA
present. (Right panel) HCV RNA levels in HCV-treated THP1 cells that were pretreated
with dimethyl sulfoxide or cytochalasin D alone for 30 minutes before HCV exposure. HCV
RNA level was determined by reverse-transcription quantitative polymerase chain reaction
and compared with GAPDH. **P = .03.
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In vitro model of acute and constitutive IFN response. (A) HCV RNA levels as compared
with GAPDH and ISG (IFIT1, MX1, OAS1, and IFITM1) expression during repeated
treatment with IFN-α in Huh7-K2040 cells (mean ± SD). (B) HCV RNA levels as compared
with GAPDH and ISG (IFIT1, ISG20, and PKR) expression during repeated treatment with
IFN-α in Huh7-L2198S cells (mean ± SD).
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Innate immune tolerance model in the treatment of chronic hepatitis C. Endogenous IFN-β
produced by myeloid cells drives basal ISG expression among hepatocytes via paracrine
signaling. ISGs impart antiviral actions through multiple processes, which are often
cytotoxic with prolonged exposure. ISGs, therefore, must be tolerated for the cell to survive.
As the cell becomes tolerized to the actions of IFN, the efficacy of IFN therapy is reduced.
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